- In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profile
- Regulatory approval process in
Europe andUnited States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in theU.S. in a global market for AFD with an estimated potential ofUSD 800 million - This milestone is part of Grifols’ robust innovation strategy, balancing internal and external investments to build a comprehensive and diversified portfolio
The FC from Biotest, a
“This successful clinical trial is a significant stride towards a potential therapy that could contribute to the care of patients who experience severe blood loss during major surgery,” said Jörg Schüttrumpf,
AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
The drawback is that they also contain other proteins and elements that aren’t necessary, so large volumes are needed to ensure enough fibrinogen. Plus both need to be thawed in advance, time consuming when lives are at risk. FC, which is also used to treat AFD, is a precision medicine in which patients on the operating table immediately receive only what’s essential to curtail hemorrhaging.
BT524 will likely enter regulatory authorization processes in Q4 2024 starting in
Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing. Grifols’ experience with it to manage surgical bleeding includes the fibrinogen-based fibrin sealant the company launched five years ago.
“The positive results for Biotest’s fibrinogen are an important milestone and strengthen a
Detailed results of the trial will be presented later this year.
Biotest, a
The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence. Furthermore, it has provided new scientific and industrial capabilities, enabling improved revenue growth and margin expansion through the introduction of innovative plasma proteins.
The step forward in BT524’s development comes in the middle of two other Biotest innovations that also highlight this company’s increasing contributions to Grifols’ profitable growth.
In late 2022, Biotest’s new immunoglobulin (Ig) Yimmugo® entered the European market and is awaiting authorization to become available in the
About Biotest’s AdFIrst trial
The trial for Biotest’s fibrinogen concentrate (FC), BT524, is known as AdFIrst (Adjusted Fibrinogen Replacement Strategy) was a prospective, active-controlled, multicenter phase 3 trial investigating the efficacy and safety of BT524 in patients with acquired fibrinogen deficiency. Patients who had high blood loss during planned spinal or abdominal surgery were randomized 1:1 to treatment with BT524 or cryoprecipitate/fresh frozen plasma (FFP). To evaluate the efficacy of BT524, further blood loss was compared between both treatment options. Further information about the trial design can be found at www.clinicaltrialsregister.eu (EudraCT number: 2017-001163-20).
The trial met its primary endpoint, demonstrating that Fibrinogen concentrate (BT524) is non-inferior to standard of care (SOC), in reducing intraoperative blood loss in patients with acquired fibrinogen deficiency undergoing planned major spinal or abdominal surgery. Mean blood loss measured in the two treatment groups were 1,444 mL in the BT524 group versus 1,735 mL in the SOC group, resulting in a reduction of blood loss of 291 mL in patients treated with fibrinogen concentrate.
About fibrinogen and fibrinogen deficiency
Fibrinogen is a blood clotting factor that is produced in the liver. It plays a key role in primary haemostasis (stopping blood loss from bleeding wounds) and wound healing. In case of a lack or shortage of fibrinogen the blood's ability to clot is impaired, which leads to a much greater risk of bleeding and delayed haemostasis.
The fibrinogen concentrate alternatives fresh frozen plasma (FFP) and cryoprecipitate contain variable amounts of fibrinogen and must be thawed prior to treatment. The defined amount of fibrinogen in the fibrinogen concentrate will allow a tailor-made, patient specific and highly effective therapy.
About
Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life.
A pioneer in the plasma industry,
As a recognized leader in transfusion medicine,
In 2022, Grifols’ economic impact in its core countries of operation was
The company’s class A shares are listed on the
For more information, please visit www.grifols.com.
MEDIA CONTACT:
Media Press Office
media@grifols.com
Tel. +34 93 571 00 02
INVESTORS:
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21
LEGAL DISCLAIMER
The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the
Source:
2024 GlobeNewswire, Inc., source